Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | Vice President, Finance | March 15, 2023 | March 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date March 15, 2023 · Filed March 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-03-14 | Direct | 125,000 |
Reported balance
After 2023-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-15 · Grant · Acquired 125,000 · Balance 125,000 F1: One-sixteenth of the shares underlying the option vest in equal quarterly installments measured from March 15, 2023, with the first vesting occuring on June 15, 2023, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-sixteenth of the shares underlying the option vest in equal quarterly installments measured from March 15, 2023, with the first vesting occuring on June 15, 2023, subject to the Reporting Person's continued service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2023 Filed Mar 18, 2023 00:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000899243-23-009001 · doc4.xml · derivative · entry 1 Wong Michael · CIK 0001895407 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: One-sixteenth of the shares underlying the option vest in equal quarterly installments measured from March 15, 2023, with the first vesting occuring on June 15, 2023, subject to the Reporting Person's continued service through each such date. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-22-031460 · doc4.xml · derivative · entry 1 Wong Michael · CIK 0001895407 · VP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-09-14 F1 · derivative.exercise_date: The options will vest in a series of sixteen equal quarterly installments measured from September 15, 2022, with the first vesting occurring on December 15, 2022, subject to the Reporting Person's continuous service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.